Prot #585-02: A Phase III, Randomized, Double-Blind, Clinical Trial of Pembrolizumab (MK-3475) plus Chemotherapy (XP or FP) versus Placebo plus Chemotherapy (XP or FP) as Neoadjuvant/Adjuvant Treatment for Subjects with Gastric and Gastroesophageal Juncti

Project: Research project

StatusActive
Effective start/end date7/19/187/19/21

Funding

  • Merck Sharp & Dohme Corp. (Prot #585-02)